Amarin Corp Plc (AMRN)

[Laurent Maldague]

Complete agreement on the currently approved AD drugs. lecanemab and donanemab both come with brain swelling/bleeding.
blacarmasine has some advantages (taken orally, no reported brain swelling issues), but has some significant drawbacks (dizziness and confusion were major side effects). There's also some unresolved questions about dosing in their latest trial.

"“In the presentations released so far, the dose groups were pooled making it unclear whether a lower dose is viable,” Dr Gourlay said.
https://www.informa.com.au/insight/beyond-the-amyloid-hypothesis-how-small-molecules-are-giving-hope-to-alzheimers-research/

Vascepa would by a landslide be the best option for AD if proven.